Curis, a drug development company, has reported a net loss of $3.38m, or $0.04 per share, for the third quarter ended 30 September 2012 compared to a net loss of $4.21m, or $0.05 per share, for the third quarter ended 30 September 2011. ...
Tags: Net Loss, proprietary and licensed programs, clinical trial